DCM
SUPN icon

Dialectic Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Dialectic Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-22,200
Closed -$338K – 125
2016
Q1 		$338K Buy
+22,200
New +$290K 0.16% 85

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.46B AUM 71.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dialectic Capital Management's SUPN Position: Q2 2016 in Review

Dialectic Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2016, closing a stake of 22,200 shares — an estimated $338K sold.

Dialectic Capital Management first reported a position in SUPN in Q1 2016 and held it in 1 quarter. The position peaked at $338K in Q1 2016. 215 funds tracked by Wall St. Rank hold SUPN as of Q2 2016.

  • Dialectic Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Dialectic Capital Management sold 22,200 Supernus Pharmaceuticals shares in Q2 2016, an estimated $338K.
  • Dialectic Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Dialectic Capital Management's Supernus Pharmaceuticals position peaked at $338K in Q1 2016.
  • 215 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2016.

Based on Dialectic Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.